港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

恆瑞醫藥

68.300

+2.6504.04%

成交量：436.21萬

成交額：2.96億

市值：4,533.07億

市盈率：50.37

高：68.550

開：67.200

低：66.800

收：65.650

52周最高：95.200

52周最低：52.500

股本：66.37億

香港流通股本：2.58億

量比：1.54

換手率：1.69%

股息：- -

股息率：- -

每股收益(LYR):1.356

淨資產收益率：14.31%

總資產收益率：8.42%

市淨率：6.44

市盈率(LYR):50.37

市銷率: 12.47

資料載入中...

總覽公司新聞資訊公告

恒瑞醫藥新總裁上任後首份年報「雙增」：仿製藥收入下降、遭默克「退貨」暴露隱憂

【灣區早參】深圳：加快智能網聯汽車商業化運營；廣州近3年首店平均年增長率超20%

恒瑞醫藥將於2026年4月16日後派發末期股息每股0.20元

恒瑞醫藥2025年創新業務發力，營收突破316億元，利潤穩步增長

恒瑞醫藥(01276)擬向上海瑞宏迪增資2.85億元

恒瑞醫藥2025年年報：營收淨利再創新高創新國際化雙輪驅動結碩果

21世纪经济报道

仿製藥業務受擠壓，中國製藥商恒瑞季度利潤不及預期

恒瑞醫藥：2025年淨利潤按年增長21.69%，擬10派2元

老虎资讯综合

愛科百發三闖港股今年1月剛獲批首款藥物；ADC藥物頭對頭對比：恒瑞醫藥挑戰德曲妥珠單抗｜掘金創新藥

每日经济新闻

政府委任四名特首顧問團新成員包括恒瑞醫藥(01276.HK)壁仞科技(06082.HK)百度(09888.HK)董事長等

阿斯达克财经

恒瑞醫藥(01276.HK)子公司SHR-3836注射液臨床試驗獲批

阿斯达克财经

恒瑞醫藥(01276.HK)SHR-A1811獲批新增適應症

阿斯达克财经

恒瑞醫藥(600276.SH)：SHR-3836注射液獲得藥物臨床試驗批

恒瑞醫藥：1類新藥注射用瑞康曲妥珠單抗新增乳腺癌適應症獲批

每日经济新闻

財報前瞻｜恒瑞醫藥研發推進與海外商業化成關注點

標普全球市場財智列出近期十大沽空比例最高港股

阿斯达克财经

港股公告掘金 | 螞蟻集團收購耀才證券金融的要約已獲批准 3月17日復牌

恒瑞醫藥(600276.SH)：SHR-1819注射液聯合SHR-1905注射液用於治療特應性皮炎獲批開展臨床試驗

恒瑞醫藥：富馬酸立康可泮膠囊的藥品上市許可申請獲受理

恒瑞醫藥獲Wellington Management Group LLP增持4.96萬股

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/01276/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":68.3,"timestamp":1776240488002,"preClose":65.65,"halted":0,"volume":4362127,"delay":0,"changeRate":0.040365575019040235,"floatShares":258000000,"shares":6637000000,"eps":1.3558823621578424,"marketStatus":"未開盤","change":2.65,"latestTime":"04-15 16:08:08","open":67.2,"high":68.55,"low":66.8,"amount":295575366,"amplitude":0.026657,"askPrice":68.3,"askSize":800,"bidPrice":68.2,"bidSize":2800,"shortable":3,"etf":0,"ttmEps":1.3558823621578424,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":65.65,"openAndCloseTimeList":[[1776216600000,1776225600000],[1776229200000,1776240000000]],"volumeRatio":1.540264056202051,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":57.73,"timestamp":1776236400000,"preClose":56.18,"halted":0,"volume":102947900,"delay":0,"premium":"+2.96"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.42%","roe":"14.31%","lyrEps":1.355882,"volumeRatio":1.540264056202051,"shares":6637000000,"dividePrice":0,"high":68.55,"amplitude":0.026657,"preClose":65.65,"low":66.8,"week52Low":52.5,"pbRate":"6.44","psRate":"12.47","week52High":95.2,"institutionHeld":0,"latestPrice":68.3,"committee":0.555556,"eps":1.3558823621578424,"divideRate":0,"volume":4362127,"delay":0,"ttmEps":1.3558823621578424,"open":67.2,"prevYearClose":71.25,"prevWeekClose":67.5,"prevMonthClose":64.5,"prevQuarterClose":64.5,"fiveDayClose":66.65,"twentyDayClose":64,"sixtyDayClose":78.7,"earningDate":1776873600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2026-04-23","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1776907800000,"name":null,"time":"","dateTimestamp":1776873600000,"actualEps":null},{"date":"2026-03-26","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null},{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1772208000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2026-04-14","current":50.361873,"percent":0.05,"low":44.415436,"twenty":50.918226,"median":54.841023,"eighty":60.15932,"high":65.582363,"avg":55.284882,"sd":4.855199,"marketCap":427765750522.06},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-21","current":52.805265,"twenty":52.880927,"median":57.030538,"eighty":62.209511,"marketCap":431684582485.14},{"date":"2025-11-28","current":55.237621,"twenty":52.99843,"median":56.630614,"eighty":62.069705,"marketCap":453209419829.34},{"date":"2025-12-05","current":54.841023,"twenty":53.00899,"median":56.437545,"eighty":61.965159,"marketCap":450729029423.46},{"date":"2025-12-12","current":56.212257,"twenty":53.045529,"median":56.385682,"eighty":61.891765,"marketCap":462853512587.19},{"date":"2025-12-19","current":54.083493,"twenty":53.045529,"median":56.227363,"eighty":61.831221,"marketCap":446374731108.34},{"date":"2025-12-24","current":54.414957,"twenty":53.090114,"median":56.103073,"eighty":61.798561,"marketCap":450509359276.9},{"date":"2026-01-02","current":53.078544,"twenty":53.065996,"median":55.972407,"eighty":61.785925,"marketCap":441174507319.22},{"date":"2026-01-09","current":56.743223,"twenty":53.0878,"median":56.0944,"eighty":61.695241,"marketCap":472808676524.34},{"date":"2026-01-16","current":55.187351,"twenty":53.304215,"median":56.103073,"eighty":61.405393,"marketCap":461338821289.95},{"date":"2026-01-23","current":52.546341,"twenty":53.0878,"median":56.076447,"eighty":61.296167,"marketCap":438839874056.97},{"date":"2026-01-30","current":51.677141,"twenty":52.994149,"median":55.908509,"eighty":61.278475,"marketCap":433553740508.2},{"date":"2026-02-06","current":50.918226,"twenty":52.680723,"median":55.839154,"eighty":61.101743,"marketCap":428270226283.58},{"date":"2026-02-13","current":51.771686,"twenty":52.512455,"median":55.711415,"eighty":60.890064,"marketCap":437949787160.49},{"date":"2026-02-20","current":51.752043,"twenty":52.351169,"median":55.691374,"eighty":60.824953,"marketCap":437153052005.04},{"date":"2026-02-27","current":50.215456,"twenty":52.151244,"median":55.507566,"eighty":60.720339,"marketCap":428825318404.97},{"date":"2026-03-06","current":49.335298,"twenty":51.80347,"median":55.280584,"eighty":60.654676,"marketCap":417912584744.19},{"date":"2026-03-13","current":48.90444,"twenty":51.75217,"median":55.201025,"eighty":60.572606,"marketCap":416170839186.33},{"date":"2026-03-20","current":48.948437,"twenty":51.671435,"median":55.086674,"eighty":60.515374,"marketCap":414967977646.95},{"date":"2026-03-27","current":47.483832,"twenty":51.400677,"median":54.94883,"eighty":60.443129,"marketCap":414588875872.42},{"date":"2026-04-02","current":49.302243,"twenty":51.107295,"median":54.905743,"eighty":60.227005,"marketCap":432534434303.11},{"date":"2026-04-10","current":49.055344,"twenty":50.995993,"median":54.897923,"eighty":60.186394,"marketCap":433687668394.36},{"date":"2026-04-14","current":48.271051,"twenty":50.918226,"median":54.841023,"eighty":60.15932,"marketCap":427765750522.06}],"updateTime":1776259951933},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622320848","title":"恒瑞醫藥新總裁上任後首份年報「雙增」：仿製藥收入下降、遭默克「退貨」暴露隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2622320848","media":"蓝鲸财经","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622320848?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:11","pubTimestamp":1774512685,"startTime":"0","endTime":"0","summary":"靓丽的财报展示了恒瑞医药这些年在创新药、国际化等领域布局的成功，但赖以发家的仿制药业务却继续出现下滑，拖累业绩增长，此外，今年三月初恒瑞医药去年大力发展的对外授权业务却遭遇重挫，产品被默克“退货”，暴露了高额授权背后的不确定性。创新药销售、对外许可双轮驱动对于营收、利润的增长的原因，恒瑞医药方面称主要系创新药销售收入增长及对外许可收入的确认。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774508291439112391","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0196","LU2023250843.SGD","SG9999014559.SGD","LU1291159041.SGD","LU0965508806.USD","LU1066053197.SGD","SG9999001440.SGD","SG9999014542.SGD","LU0289739699.SGD","LU1069347547.HKD","LU2289578879.USD","LU0965509101.SGD","LU1035773651.USD","LU0006306889.USD","BK0183","BK4007","LU2097828557.USD","IE00BJT1NW94.SGD","LU1116320737.USD","LU2097828474.EUR","SG9999014575.USD","LU1162221912.USD","LU1997245177.USD","LU1430594728.SGD","LU0980610538.SGD","LU2328871848.SGD","LU1580142542.USD","LU1969619763.USD","LU0868494708.USD","SG9999001176.USD","IE00B1BXHZ80.USD","LU0432979614.USD","LU2361045086.USD","SG9999013999.USD","LU0265550946.USD","LU1116320901.HKD","LU2468319806.SGD","BK4559","LU1066051225.USD","BK4533","LU1699723380.USD","LU2089984988.USD","BK4585","LU0070302665.USD","LU0130517989.USD","LU0058720904.USD","LU1023057109.AUD","LU2580892789.USD","LU0861579265.USD","LU2360032135.SGD","SG9999001176.SGD","LU0203345920.USD","LU1037948541.HKD","IE00BN8TJ469.HKD","LU0122379950.USD","LU0130102774.USD","IE00BLSP4452.SGD","BK4534","LU1934455863.HKD","LU0211331839.USD","LU1023059063.AUD","LU0208291251.USD","LU1655091616.SGD","LU1989772923.USD","SG9999015358.SGD","LU1989772840.SGD","LU0405327148.USD","LU2361044865.SGD","LU2112291526.USD","LU2324357040.USD","LU0985320562.USD","BK4550","LU0098860793.USD","LU1941712348.USD","LU2106854487.HKD","IE00B2B36J28.USD","LU0320765646.SGD","LU1146622755.USD","LU1064131003.USD","LU1917777945.USD","LU1064130708.USD","01276","IE0002141913.USD","LU0359201885.HKD","LU1093756168.USD","LU0266013472.USD","SG9999002224.SGD","LU2148510915.USD","BK0012","LU0477156953.USD","LU2097828714.EUR","LU1037948897.HKD","BK0060","LU0405327494.USD","LU2125154778.USD","BK0188","LU2543165471.USD","SGXZ57979304.SGD","LU1066051811.HKD","BK1191","LU2495084118.USD","LU1061106388.HKD","LU2488822045.USD","IE00BBT3K403.USD","BK0028","LU0965509010.AUD","LU1989771016.USD","LU0942090050.USD","IE00BSNM7G36.USD","LU1781817850.SGD","LU0359202008.SGD","LU1941712264.USD","LU1934455277.USD","LU0234572021.USD","BK4588","LU2097828631.EUR","LU0265550359.USD","LU1066051498.USD","600276","LU1820825898.SGD","BK0239","LU1571399168.USD","LU1057294990.SGD","LU1983299246.USD","LU2125154935.USD","LU1974910355.USD","LU1093756325.SGD","LU1328615791.USD","LU0320765489.SGD","LU1997245094.SGD","LU2097828805.USD","SG9999014567.USD","LU1997244956.HKD","BK4516","LU0965509283.SGD","LU2461242641.AUD","IE00BFTCPJ56.SGD","LU0203347892.USD","LU0238689110.USD","LU1201861249.SGD","SG9999002232.USD","LU0106261372.USD","IE0009355771.USD","LU1255011170.USD","LU1934455194.USD","LU2023250504.SGD","LU0868494617.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE000M9KFDE8.USD","LU1585245621.USD","LU1929549753.HKD","LU0359201612.USD","LU2361044949.HKD","LU2580892862.HKD","SG9999015341.SGD","IE00BLSP4239.USD","LU0648001328.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622688645","title":"【灣區早參】深圳：加快智能網聯汽車商業化運營；廣州近3年首店平均年增長率超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622688645","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622688645?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 08:30","pubTimestamp":1774485010,"startTime":"0","endTime":"0","summary":"方案提出，加快智能网联汽车商业化运营。全年经调整净利润达到206亿元，同比增长16.5%，经调整净利润率为14.5%。期内，公司收入62.3亿港元，同比增长40.9%。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977280","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1051768304.USD","LU0471298777.SGD","LU0228659784.USD","BK1526","LU0823426308.USD","LU0211977185.USD","BK1613","01276","LU0072462343.USD","LU0307460666.USD","LU0370786039.SGD","BK1531","LU0326950275.SGD","BK1104","IE0031814852.USD","LU0385154629.USD","IE00B031J352.USD","LU0359201612.USD","LU0588546209.SGD","LU0348788117.USD","BK1589","MUCmain","IE0008369823.USD","LU1102505929.USD","BK1237","BK1539","MCNHmain","CYB","01788","SG9999002828.SGD","UCmain","LU0315179316.USD","IE00B031HY20.USD","LU0594300419.USD","03888","BK1597","BK1607","BK1521","CNHmain","LU0173614495.USD","LU0029875118.USD","02319","01958","BK1191","LU1769817179.HKD","IE00B29SXG58.USD","LU0640798160.USD","LU0672654166.SGD","BK1586","LU0737861699.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137906506","title":"恒瑞醫藥將於2026年4月16日後派發末期股息每股0.20元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137906506","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137906506?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 06:35","pubTimestamp":1774478157,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276)\n2026年3月25日，恒瑞医药公布，截至2025年12月31日止年度拟派发末期股息，每10股派发2元人民币，即每股0.20元，尚需于2026年4月16日股东大会批准后发放。公司表示，若分红派息记录日公司总股本发生变化，派发方案的每股分配比例将保持不变，并相应调增分配总额。另外，关于港股除净日、股份过户登记的最后时限、记录日期及具体派息日期等事项尚待后续公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138271280","title":"恒瑞醫藥2025年創新業務發力，營收突破316億元，利潤穩步增長","url":"https://stock-news.laohu8.com/highlight/detail?id=1138271280","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138271280?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 06:29","pubTimestamp":1774477778,"startTime":"0","endTime":"0","summary":"恒瑞医药于2025年度实现营业收入316.29亿元，同比增长13.0%；同期录得归属于上市公司股东的利润77.11亿元，同比上升7.7%。报告期内，公司在肿瘤、心血管、免疫和神经系统等多个治疗领域持续深耕，创新药销售收入约163.42亿元，增幅达26.1%，并带动整体业绩稳步提升。公司报告期内在境内外持续推动合作与新药注册申请，提升新产品的临床价值与商业化效率。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622678070","title":"恒瑞醫藥(01276)擬向上海瑞宏迪增資2.85億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622678070","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622678070?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 23:20","pubTimestamp":1774452011,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公布，于2026年3月25日，公司与恒瑞集团、盛迪生物医药基金、深圳迎泰及上海瑞宏迪订立增资协议，以将上海瑞宏迪的注册资本由约人民币1.316亿元增加至约2.303亿元。根据增资协议，公司、恒瑞集团、盛迪生物医药基金及深圳迎泰同意按比例以现金形式出资合共人民币7.5亿元，该公司出资2.85亿元。增资协议完成后，公司、恒瑞集团、盛迪生物医药基金及深圳迎泰将分别继续持有上海瑞宏迪38.0%、28.0%、19.0%及15.0%的股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1781817850.SGD","BK0196","LU0359202008.SGD","LU1146622755.USD","LU1064131003.USD","LU2097828631.EUR","LU2289578879.USD","LU1064130708.USD","600276","LU1820825898.SGD","BK0239","01276","LU1023057109.AUD","LU0359201885.HKD","LU1328615791.USD","LU2580892789.USD","BK0183","LU1997245094.SGD","LU2097828557.USD","LU2097828805.USD","LU1997244956.HKD","LU2097828474.EUR","LU2148510915.USD","BK0012","LU1997245177.USD","LU2097828714.EUR","BK0060","LU0405327494.USD","LU2328871848.SGD","LU1580142542.USD","LU1969619763.USD","BK0188","LU2543165471.USD","LU1655091616.SGD","LU1255011170.USD","LU2495084118.USD","BK1191","LU2488822045.USD","LU0405327148.USD","BK0028","LU0359201612.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072044","title":"恒瑞醫藥2025年年報：營收淨利再創新高 創新國際化雙輪驅動結碩果","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072044","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072044?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 22:22","pubTimestamp":1774448520,"startTime":"0","endTime":"0","summary":"3月25日，恒瑞医药发布2025年年度报告。报告期内，公司坚持“科技创新+国际化”双轮驱动战略，实现业绩持续增长，营收和净利均再创新高。全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%；归属于上市公司股东的扣除非经常性损益的净利润74.13亿元，同比增长20.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603253684444032.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253684444032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622071357","title":"仿製藥業務受擠壓，中國製藥商恒瑞季度利潤不及預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071357","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622071357?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 21:32","pubTimestamp":1774445526,"startTime":"0","endTime":"0","summary":"路透上海3月25日 - 中国市值最大的制药企业江苏恒瑞医药600276.SS周三公布的第四季度利润低于市场预期，原因是业务开发交易的收入未能显现。恒瑞在其年报中表示，2025年恒瑞的创新药销售收入增长了26.09%，但仿制药收入有所下滑。该公司年报显示，截至12月31日的一季度，该公司实现归属于股东的净利润19.6亿元，低于汇丰前海证券分析师预计的27亿元。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D1AH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0239","LU1116320901.HKD","SG9999014559.SGD","LU1061106388.HKD","LU1655091616.SGD","LU1064131003.USD","LU0405327148.USD","LU1929549753.HKD","LU0289739699.SGD","LU0130102774.USD","LU1328615791.USD","BK0183","LU0006306889.USD","SG9999015358.SGD","IE00BJT1NW94.SGD","BK4559","LU1057294990.SGD","LU1291159041.SGD","LU2097828714.EUR","LU1201861249.SGD","LU1917777945.USD","LU2360032135.SGD","LU2106854487.HKD","BK4550","LU0985320562.USD","IE00BJJMRZ35.SGD","LU0070302665.USD","BK4533","IE00BSNM7G36.USD","01276","LU1069347547.HKD","IE0002141913.USD","IE0009355771.USD","LU2097828805.USD","LU2580892862.HKD","LU0868494617.USD","LU1066051811.HKD","BK0028","LU0208291251.USD","600276","IE00BLSP4239.USD","LU1997244956.HKD","LU0203345920.USD","LU0234572021.USD","LU2097828557.USD","LU2289578879.USD","IE00BLSP4452.SGD","LU1430594728.SGD","IE00B2B36J28.USD","LU1023059063.AUD","LU1820825898.SGD","SG9999014542.SGD","IE00BBT3K403.USD","LU1989772923.USD","LU2324357040.USD","BK4534","LU0965509283.SGD","LU2328871848.SGD","LU0405327494.USD","LU1969619763.USD","SG9999002232.USD","LU1093756325.SGD","LU0320765646.SGD","LU1037948897.HKD","LU2125154935.USD","LU0942090050.USD","SGXZ57979304.SGD","SG9999015341.SGD","LU0980610538.SGD","LU1066051225.USD","LU0965509010.AUD","BK0188","LU2023250504.SGD","SG9999014567.USD","LU0868494708.USD","BK0060","LU1997245094.SGD","LU1934455863.HKD","LU1066053197.SGD","LU0098860793.USD","LU1066051498.USD","BK4588","LU1974910355.USD","LU1571399168.USD","SG9999001176.SGD","SG9999013999.USD","IE00BFTCPJ56.SGD","IE00B1BXHZ80.USD","LU0238689110.USD","LU1699723380.USD","SG9999001440.SGD","LU2361045086.USD","LU0477156953.USD","LU2461242641.AUD","LU1997245177.USD","BK4007","LU2468319806.SGD","LU0106261372.USD","LU1064130708.USD","LU2495084118.USD","LU0320765489.SGD","LU1580142542.USD","BK0196","LU1585245621.USD","LU2361044865.SGD","LU2112291526.USD","IE00B4R5TH58.HKD","LU1934455277.USD","LU1989771016.USD","LU0122379950.USD","LU0266013472.USD","LU1941712264.USD","LU2089984988.USD","LU2148510915.USD","LU1162221912.USD","LU0861579265.USD","LU0965508806.USD","LU0965509101.SGD","LU1934455194.USD","LU2097828631.EUR","LU0130517989.USD","LU1116320737.USD","BK4516","IE000M9KFDE8.USD","LU0203347892.USD","LU1941712348.USD","BK4585","LU0432979614.USD","LU2488822045.USD","LU1781817850.SGD","LU2580892789.USD","LU0648001328.SGD","SG9999001176.USD","LU2023250843.SGD","LU1035773651.USD","IE00BN8TJ469.HKD","LU1037948541.HKD","LU1255011170.USD","SG9999014575.USD","LU1093756168.USD","LU0211331839.USD","LU0265550359.USD","LU2097828474.EUR","LU1146622755.USD","LU1983299246.USD","LU2361044949.HKD","SG9999002224.SGD","LU0265550946.USD","LU0058720904.USD","LU1989772840.SGD","LU2125154778.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167610912","title":"恒瑞醫藥：2025年淨利潤按年增長21.69%，擬10派2元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167610912","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167610912?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 20:47","pubTimestamp":1774442842,"startTime":"0","endTime":"0","summary":"3月25日，$恒瑞医药(01276)$公告称，2025年公司实现营收316.29亿元，同比增长13.02%；净利润77.11亿元，同比增长21.69%。拟向全体股东按每10股派发现金股利2.00元（含税）。小财注：Q3净利润13.01亿，据此计算，Q4净利润19.6亿，环比增长50%。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药：2025年净利润同比增长21.69%，拟10派2元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023057109.AUD","BK1191","LU1580142542.USD","LU1781817850.SGD","LU2488822045.USD","BK0188","LU2097828474.EUR","LU2097828557.USD","LU2289578879.USD","LU1969619763.USD","BK0183","LU1655091616.SGD","BK0060","LU1997245094.SGD","LU1255011170.USD","LU1997245177.USD","LU2495084118.USD","LU1146622755.USD","LU0405327494.USD","LU2097828805.USD","LU2543165471.USD","LU2580892862.HKD","LU0405327148.USD","BK0012","LU2328871848.SGD","LU0359201612.USD","600276","LU2097828714.EUR","LU1064131003.USD","LU2148510915.USD","01276","LU0359202008.SGD","BK0239","BK0028","LU2097828631.EUR","BK0196","LU1997244956.HKD","LU1328615791.USD","LU1064130708.USD","LU2580892789.USD","LU1820825898.SGD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621093082","title":"愛科百發三闖港股 今年1月剛獲批首款藥物；ADC藥物頭對頭對比：恒瑞醫藥挑戰德曲妥珠單抗｜掘金創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2621093082","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621093082?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 22:16","pubTimestamp":1774361773,"startTime":"0","endTime":"0","summary":"一周行情上周（3月16日至3月20日）医药生物指数下跌1.38%，跑赢上证指数2个百分点。创新药（BK1106）周内下跌3.57%；恒生医疗保健业指数（HSCICH）周内下跌0.33%；港股创新药ETF（513120）周内下跌0.14%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682906186.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682906186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","VXUS","LU1580142542.USD","01276","LU2580892789.USD","BK1191","BK4585","BK1161","LU2495084118.USD","LU2543165471.USD","LU1997245177.USD","LU1969619763.USD","LU0359201885.HKD","BK0183","600276","LU2097828714.EUR","LU1064131003.USD","LU1820825898.SGD","LU2580892862.HKD","BK0188","LU0359201612.USD","BK4231","LU1328615791.USD","BK1574","LU1781817850.SGD","LU1997245094.SGD","BK4588","LU1146622755.USD","LU2097828474.EUR","LU2097828805.USD","LU2097828631.EUR","LU0359202008.SGD","LU1064130708.USD","ADC","LU1023057109.AUD","LU2148510915.USD","LU2289578879.USD","159992","LU2488822045.USD","LU0405327494.USD","LU2097828557.USD","BK0060","BK4080","LU2328871848.SGD","LU0405327148.USD","LU1255011170.USD","BK0028","BK0239","BK0012","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063001","title":"政府委任四名特首顧問團新成員  包括恒瑞醫藥(01276.HK)壁仞科技(06082.HK)百度(09888.HK)董事長等","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063001","media":"阿斯达克财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063001?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 18:11","pubTimestamp":1774347060,"startTime":"0","endTime":"0","summary":"政府今日宣布委任四名特首顾问团新成员。有关任期由今年4月1日起生效，至明年6月30日止，包括恒瑞医药董事长孙飘扬、赛昉科技创始人兼CEO徐滔、壁仞科技创始人、董事长、CEO张文，以及百度-SW联合创始人、董事长兼CEO李彦宏。获委任的新成员均是硬科技及生命科技等前沿领域的业界翘楚，他们的参与将进一步拓展特首顾问团的专业领域。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220802135129703_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220802135129703_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511951/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511951/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1115378108.SGD","LU0417516902.SGD","LU1328615791.USD","09888","LU2476274308.USD","BK1163","LU2148510915.USD","SG9999002828.SGD","LU0315179316.USD","LU0762540952.USD","LU0823426480.USD","LU0531971595.HKD","LU1997244956.HKD","LU2097828714.EUR","BK0060","LU0463099449.HKD","LU0630378692.HKD","LU0588546209.SGD","89888","LU0405327148.USD","LU0173614495.USD","HK0000306685.HKD","BK0012","BK0239","LU0163747925.USD","BK1609","LU0164880469.USD","LU2328871848.SGD","BK1095","LU0051755006.USD","LU1997245177.USD","IE0034224299.USD","LU0819121731.USD","SG9999002463.SGD","LU1969619763.USD","LU2495084118.USD","BK1588","LU0359201885.HKD","LU2097828474.EUR","LU1781817850.SGD","BK1587","LU2097828557.USD","LU0043850808.USD","LU2039709279.SGD","LU0831093199.SGD","LU0856984785.SGD","LU0326950275.SGD","LU0762542818.HKD","LU1146622755.USD","LU0871576103.HKD","06082","LU0197773673.USD","600276","LU0348825331.USD","BK1575","LU0823426308.USD","LU0307460666.USD","LU0405327494.USD","HK0000306701.USD","LU2580892789.USD","BK0028","LU1820825898.SGD","LU1655091616.SGD","LU0762541174.USD","LU0287142896.SGD","LU1831875114.USD","LU2097828805.USD","LU0708995583.HKD","BK1615","LU2289578879.USD","LU2543165471.USD","LU1023057109.AUD","LU0244354667.USD","SG9999014674.SGD","LU0197773160.USD","LU1481107354.HKD","LU0456827905.SGD","HK0000320223.HKD","LU1064131003.USD","LU2097828631.EUR","LU1255011170.USD","LU0052750758.USD","LU0821914370.USD","BK0183","LU1580142542.USD","LU0228367735.SGD","LU0039217434.USD","LU0630378429.USD","LU0320764599.SGD","LU2778985437.USD","BK0188","LU1064130708.USD","LU1048596156.SGD","LU0543330566.HKD","LU0348735423.USD","LU1188198961.HKD","LU0417516738.SGD","LU0640798160.USD","01276","BK0196","HK0000320264.USD","LU0359202008.SGD","LU0072462343.USD","LU0164865239.USD","LU1997245094.SGD","BK1191","LU2580892862.HKD","LU0359201612.USD","LU2488822045.USD","LU0149721374.USD","LU1048588211.SGD","LU0229945570.USD","BIDU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621139507","title":"恒瑞醫藥(01276.HK)子公司SHR-3836注射液臨床試驗獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2621139507","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621139507?lang=zh_tw&edition=fundamental","pubTime":"2026-03-22 11:58","pubTimestamp":1774151880,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276.HK) 公布，子公司上海恒瑞收到国家药品监督管理局核准签发关于SHR-3836注射液的药物临床试验批准通知书，同意本品单药在多发性骨髓瘤中开展临床试验。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-20 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250911164657656_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250911164657656_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511095/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511095/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0188","BK0012","LU1997244956.HKD","LU0405327494.USD","LU1023057109.AUD","LU1255011170.USD","LU2148510915.USD","BK0028","LU2097828557.USD","LU1781817850.SGD","LU1064130708.USD","BK0060","LU0359201612.USD","LU1997245177.USD","BK0239","LU1969619763.USD","LU1064131003.USD","LU2328871848.SGD","LU1655091616.SGD","LU1580142542.USD","LU2289578879.USD","LU2488822045.USD","01276","600276","LU1997245094.SGD","LU0359202008.SGD","BK0183","BK1191","LU1146622755.USD","LU2495084118.USD","LU2580892862.HKD","LU2097828714.EUR","BK0196","LU2097828474.EUR","LU2097828805.USD","LU2580892789.USD","LU1820825898.SGD","LU2543165471.USD","LU0405327148.USD","LU0359201885.HKD","LU1328615791.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621713988","title":"恒瑞醫藥(01276.HK)SHR-A1811獲批新增適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=2621713988","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621713988?lang=zh_tw&edition=fundamental","pubTime":"2026-03-22 11:57","pubTimestamp":1774151820,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276.HK) 公布，子公司苏州盛迪亚收到国家药品监督管理局通知，批准公司自主研发的1类创新药注射用瑞康曲妥珠单抗(SHR-A1811)新增适应症，为本品适用于治疗既往接受过一种或一种以上抗HER2药物治疗的局部晚期或转移性HER2阳性成人乳腺癌患者。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-20 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131528273_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131528273_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511093/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511093/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1781817850.SGD","BK0196","LU0359202008.SGD","LU1146622755.USD","LU1064131003.USD","LU2097828631.EUR","LU2289578879.USD","LU1064130708.USD","600276","LU1820825898.SGD","BK0239","01276","LU1023057109.AUD","LU0359201885.HKD","LU1328615791.USD","LU2580892789.USD","BK0183","LU1997245094.SGD","LU2097828557.USD","LU2097828805.USD","LU1997244956.HKD","LU2097828474.EUR","LU2148510915.USD","BK0012","LU1997245177.USD","LU2097828714.EUR","BK0060","LU0405327494.USD","LU2328871848.SGD","LU1580142542.USD","LU1969619763.USD","BK0188","LU2543165471.USD","LU1655091616.SGD","LU1255011170.USD","LU2495084118.USD","BK1191","LU2488822045.USD","LU0405327148.USD","BK0028","LU0359201612.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620978152","title":"恒瑞醫藥(600276.SH)：SHR-3836注射液獲得藥物臨床試驗批","url":"https://stock-news.laohu8.com/highlight/detail?id=2620978152","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620978152?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 17:10","pubTimestamp":1773997815,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司上海恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-3836注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-3836注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗多发性骨髓瘤。经查询，目前国内外尚无同类药上市。截至目前，SHR-3836注射液相关项目累计研发投入约3,170万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU1146622755.USD","LU2328871848.SGD","LU1064130708.USD","LU2580892789.USD","BK0012","LU2289578879.USD","LU1997245177.USD","LU2097828474.EUR","LU0405327494.USD","LU2097828805.USD","LU1328615791.USD","LU1064131003.USD","LU0405327148.USD","LU1781817850.SGD","BK0028","LU1997244956.HKD","BK0183","BK0060","LU0359201885.HKD","LU2488822045.USD","LU1655091616.SGD","LU1023057109.AUD","LU1580142542.USD","LU1820825898.SGD","LU2495084118.USD","BK0239","LU2580892862.HKD","LU0359202008.SGD","BK1191","LU1255011170.USD","LU1969619763.USD","01276","600276","BK0188","LU2543165471.USD","LU0359201612.USD","LU2097828631.EUR","LU2148510915.USD","LU1997245094.SGD","LU2097828714.EUR","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620378159","title":"恒瑞醫藥：1類新藥注射用瑞康曲妥珠單抗新增乳腺癌適應症獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2620378159","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620378159?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 17:09","pubTimestamp":1773997757,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月20日，恒瑞医药(600276.SH)公告称，公司子公司苏州盛迪亚生物医药有限公司收到国家药监局通知，批准其自主研发的1类创新药注射用瑞康曲妥珠单抗(SHR-A1811)新增适应症，用于治疗既往接受过一种或以上抗HER2药物治疗的局部晚期或转移性HER2阳性成人乳腺癌患者。该药已于2025年5月首次获批用于HER2突变非小细胞肺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603203678970213.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603203678970213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0188","600276","LU1969619763.USD","LU1064130708.USD","LU0405327494.USD","LU1580142542.USD","LU2488822045.USD","LU1328615791.USD","LU1997244956.HKD","LU2580892862.HKD","BK0196","LU2097828805.USD","LU2580892789.USD","LU2097828557.USD","LU1064131003.USD","BK0183","LU1655091616.SGD","LU0359201612.USD","LU1023057109.AUD","LU1820825898.SGD","LU0405327148.USD","BK0012","LU2097828474.EUR","LU1997245177.USD","BK0028","LU2328871848.SGD","LU1997245094.SGD","LU2097828714.EUR","LU2289578879.USD","LU2495084118.USD","LU2097828631.EUR","01276","LU0359201885.HKD","LU2543165471.USD","LU0359202008.SGD","LU1255011170.USD","BK1191","LU2148510915.USD","BK0060","LU1781817850.SGD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118636156","title":"財報前瞻 ｜恒瑞醫藥研發推進與海外商業化成關注點","url":"https://stock-news.laohu8.com/highlight/detail?id=1118636156","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118636156?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 10:11","pubTimestamp":1773886299,"startTime":"0","endTime":"0","summary":"恒瑞医药将于2026年03月26日（盘后）发布最新季度业绩，市场关注产品结构升级对毛利率与利润韧性的影响。目前缺乏可核验的一致预测与公司针对本季度的量化指引，暂无法给出本季度营业收入、毛利率、净利润或净利率、调整后每股收益及其同比的预测数据。上季度公司实现营业收入157.61亿、毛利率85.58%、归属于母公司股东的净利润13.01亿、净利率17.52%，调整后每股收益未披露；归母净利润环比变动为-49.49%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 ｜恒瑞医药研发推进与海外商业化成关注点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620078416","title":"標普全球市場財智列出近期十大沽空比例最高港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620078416","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620078416?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 09:21","pubTimestamp":1773710460,"startTime":"0","endTime":"0","summary":"标普全球市场财智列出截至上周五在香港十大沽空比例最高港股。数据是根据来自标普全球市场财智的证券金融数据集计算得出。计算沽空的指标为借出股份占已发行股份总数的百分比。沽空资料截至 2026-03-16 16:25。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190627142633458_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190627142633458_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1509620/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1509620/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0140636845.USD","LU0634319403.HKD","LU0605514214.HKD","BK1505","LU1794554557.SGD","LU1366334578.USD","LU1282651121.HKD","BK1526","IE00BZ08YT58.USD","LU1813983027.USD","LU1282648689.USD","LU0898667661.SGD","LU1328277881.USD","LU0611395673.USD","IE0008368742.USD","LU0862451837.USD","LU0370786039.SGD","LU0791590937.USD","LU0572944931.SGD","LU0449515922.USD","02318","IE00BVYPNQ40.USD","LU0326950275.SGD","PNGAY","LU0821914370.USD","LU1048596156.SGD","LU0762541174.USD","LU1719994722.HKD","LU0348788117.USD","SG9999001903.USD","LU0327786744.USD","LU1282649810.SGD","LU0828237940.HKD","IE0008369823.USD","LU1993786604.SGD","03750","LU0831093199.SGD","LU0348735423.USD","LU0831103253.SGD","LU0463099449.HKD","LU0328353924.USD","BK1183","BK1590","LU0084288322.USD","LU2348774022.SGD","LU2778985437.USD","PAImain","601919","LU0043850808.USD","01072","LU0181495838.USD","LU0254981946.USD","LU0594300419.USD","LU0762540952.USD","LU1880383366.USD","LU1655091459.SGD","LU2152927971.USD","LU1515016050.SGD","LU0244354667.USD","LU0197773160.USD","SG9999004220.SGD","LU0865486749.SGD","LU1720050803.USD","02050","LU1961090484.USD","LU1807302812.USD","SG9999002562.SGD","LU0164872284.USD","LU0359201885.HKD","LU0650527681.SGD","03145","LU0918141705.HKD","BK1116","LU0588545730.USD","LU0049112450.USD","LU1105468828.SGD","LU0228659784.USD","LU0823426308.USD","LU0871576103.HKD","BK1535","LU0594300179.USD","LU0708995583.HKD","LU0856984785.SGD","LU0228367735.SGD","LU0918141887.USD","LU0211977185.USD","LU0197773673.USD","01276","LU0648948544.HKD","LU2293587155.HKD","IE00BMCWC346.EUR","LU0072462343.USD","LU1046422090.SGD","LU0675040207.SGD","LU0488056044.USD","IE00BF5LJ272.USD","LU0441854154.USD","LU2399975544.HKD","BK1240","BK1103","LU1224444064.USD","LU1831875114.USD","LU1235295612.USD","LU1008478684.HKD","BK1589","HK0001040168.HKD","LU1152091754.HKD","LU0072913022.USD","IE0034224299.USD","LU0051755006.USD","LU1303224171.USD","IE00BYV24P56.USD","LU0651947912.USD","LU2039709279.SGD","LU2153591404.USD","LU0882747503.HKD","LU0417516902.SGD","SG9999002828.SGD","82318","LU1188198961.HKD","LU0106959298.USD","LU0196878994.USD","LU0348783662.USD","SG9999014674.SGD","LU1282649067.USD","LU0359202008.SGD","LU0165289439.USD","LU1282649141.HKD","BK1506","LU2153592121.USD","LU2348773727.SGD","00763","HK0000306685.HKD","LU0052750758.USD","300750","LU0210527791.USD","SG9999011746.SGD","LU0540923850.HKD","LU1880383440.USD","LU0417516738.SGD","LU0348784397.USD","LU0011963245.USD","LU0315178854.USD","LU0588545904.SGD","LU1044874839.SGD","LU1481107354.HKD","LU0890818403.SGD","LU1044875133.USD","BK1518","SG9999001440.SGD","BK1205","LU0149534421.HKD","LU0235996351.USD","LU0651946864.USD","IE00BVYPNP33.GBP","02768","BK1550","LU0588546209.SGD","LU0862451753.SGD","LU0048580855.USD","LU0630378429.USD","IE0032431581.USD","LU0314109678.HKD","BK1516","LU0630378692.HKD","LU1820825898.SGD","LU1960683339.HKD","LU1044876610.USD","HPAD.SI","LU0348825331.USD","IE0003895053.USD","LU0607220059.USD","LU0117844026.USD","LU1115378108.SGD","LU0878004406.USD","BK1507","IE00B031HY20.USD","LU0348816934.USD","LU2476274720.SGD","LU1211504680.USD","LU0791591158.USD","BK1607","BK1521","LU0417516571.SGD","BK1546","LU2476274308.USD","LU0106252389.USD","LU0588545490.SGD","IE00BZ08YR35.GBP","BK1184","HK0000320223.HKD","HK0000320264.USD","LU1152091168.USD","BK1191","LU0823426480.USD","SG9999000459.SGD","BK1109","IE00B29SXG58.USD","LU0348827113.USD","600276","LU0049853897.USD","IE00BZ08YS42.EUR","LU0762542818.HKD","LU0348805143.USD","LU0315179316.USD","LU1366334651.USD","LU0531971595.HKD","LU1642822792.SGD","LU0149721374.USD","LU1051768304.USD","LU1769817096.USD","LU0456827905.SGD","SG9999002463.SGD","002050","LU0819121731.USD","000063","LU1023057109.AUD","LU1282651048.USD","BK1529","LU0039217434.USD","LU0293314216.USD","LU0307460666.USD","LU0067412154.USD","601318","LU1251922891.USD","LU2424517915.HKD","BK1149","LU0359201612.USD","IE00BGHQDM52.EUR","02013","HK0000306701.USD","LU0054450605.USD","LU0320764599.SGD","LU0348814723.USD","002768","LU0164865239.USD","LU0828237510.HKD","LU0348783233.USD","LU1226287529.USD","LU1770034418.SGD","BK1110","LU0163747925.USD","LU1048588211.SGD","09660","LU1146622755.USD","LU0501845795.SGD","600875","LU1051769294.HKD","LU0561508036.HKD","LU0819123356.HKD","BK1610","BK1522","LU1981816686.USD","LU2226246903.HKD","LU2543165471.USD","LU0384037296.USD","LU0784639295.USD","LU1769817179.HKD","LU0640798160.USD","LU0164880469.USD","LU0797268264.HKD","01919","LU0880133367.SGD","LU0878005551.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620241656","title":"港股公告掘金 | 螞蟻集團收購耀才證券金融的要約已獲批准 3月17日復牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2620241656","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620241656?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 09:04","pubTimestamp":1773709477,"startTime":"0","endTime":"0","summary":"重大事项：恒瑞医药(01276)：SHR-1819注射液、SHR-1905注射液获得药物临床试验批准通知书复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准白云山(00874)：虚汗停颗粒用于儿童反复呼吸道感染的临床试验申请获批派格生物医药-B(02565)与腾瑞制药达成派达康中国大陆独家商业化合作 商业化目标累计销售规","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"808c1f0b8ebd0042a82fe4057566a434","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023057109.AUD","02565","HK0000306685.HKD","01276","BK1606","LU0359201885.HKD","BK1191","BK1147","BK4585","HK0000306701.USD","BK1161","HK0000320223.HKD","LU2543165471.USD","BK1515","01428","LU0359201612.USD","VXUS","HK0000320264.USD","LU0359202008.SGD","02696","BK1197","HK0000165453.HKD","06688","00874","BK1521","BK4588"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619565624","title":"恒瑞醫藥(600276.SH)：SHR-1819注射液聯合SHR-1905注射液用於治療特應性皮炎獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2619565624","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619565624?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 17:17","pubTimestamp":1773652643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-1819注射液、SHR-1905注射液的《药物临床试验批准通知书》。经审查，2025年12月18日受理的SHR-1819注射液、SHR-1905注射液符审批结论合药品注册的有关要求，同意开展临床试验。申请的适应症：SHR-1819注射液联合SHR-1905注射液用于治疗特应性皮炎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0012","BK0239","BK0060","LU1997244956.HKD","LU1997245094.SGD","LU1655091616.SGD","LU1023057109.AUD","LU0405327148.USD","LU1064131003.USD","LU2148510915.USD","LU2097828631.EUR","LU1328615791.USD","BK0183","LU2097828557.USD","LU0359201885.HKD","LU2289578879.USD","LU2097828714.EUR","LU1820825898.SGD","LU2488822045.USD","LU1781817850.SGD","LU2543165471.USD","LU2580892789.USD","LU1997245177.USD","LU2328871848.SGD","LU0405327494.USD","LU1064130708.USD","LU1255011170.USD","LU1969619763.USD","LU2495084118.USD","LU1580142542.USD","01276","LU2097828474.EUR","LU1146622755.USD","LU2097828805.USD","BK0196","LU0359201612.USD","BK1191","LU0359202008.SGD","LU2580892862.HKD","BK0028","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619557654","title":"恒瑞醫藥：富馬酸立康可泮膠囊的藥品上市許可申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2619557654","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619557654?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 17:10","pubTimestamp":1773652230,"startTime":"0","endTime":"0","summary":"【恒瑞医药：富马酸立康可泮胶囊的药品上市许可申请获受理】恒瑞医药(600276)3月16日公告，近日，子公司成都盛迪医药有限公司收到国家药监局下发的受理通知书，富马酸立康可泮（HRS-5965）胶囊的药品上市许可申请获国家药监局受理。子公司广东恒瑞医药有限公司收到国家药监局核准签发关于SHR-1819注射液、SHR-1905注射液的药物临床试验批准通知书，将于近期开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163673173239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU0405327148.USD","01276","LU0405327494.USD","LU2328871848.SGD","BK0196","LU2543165471.USD","LU2580892789.USD","LU0359202008.SGD","LU0359201885.HKD","LU1328615791.USD","600276","LU1820825898.SGD","LU2097828714.EUR","LU2289578879.USD","LU1023057109.AUD","LU1255011170.USD","LU2495084118.USD","LU2148510915.USD","LU1969619763.USD","LU1064131003.USD","LU1997245094.SGD","LU2097828557.USD","BK0060","BK0012","BK1191","LU1580142542.USD","LU1997245177.USD","LU1064130708.USD","LU2097828805.USD","LU2580892862.HKD","LU0359201612.USD","BK0183","LU2097828631.EUR","LU1781817850.SGD","LU1146622755.USD","BK0239","LU2488822045.USD","LU2097828474.EUR","BK0188","LU1997244956.HKD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619170749","title":"恒瑞醫藥獲Wellington Management Group LLP增持4.96萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619170749","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619170749?lang=zh_tw&edition=fundamental","pubTime":"2026-03-15 15:28","pubTimestamp":1773559680,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新数据显示，3月11日，Wellington Management Group LLP增持恒瑞医药（01276）4.96万股，每股作价66.1267港元，总金额约为327.99万港元。增持后最新持股数目约为2324.44万股，持股比例为9.00%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-15/doc-inhqzzfv9634355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","LU0405327148.USD","01276","LU0405327494.USD","LU2328871848.SGD","BK0196","LU2543165471.USD","LU2580892789.USD","LU0359202008.SGD","LU0359201885.HKD","LU1328615791.USD","600276","LU1820825898.SGD","LU2097828714.EUR","LU2289578879.USD","LU1023057109.AUD","LU1255011170.USD","LU2495084118.USD","LU2148510915.USD","LU1969619763.USD","LU1064131003.USD","LU1997245094.SGD","LU2097828557.USD","BK0060","BK0012","BK1191","LU1580142542.USD","LU1997245177.USD","LU1064130708.USD","LU2097828805.USD","LU2580892862.HKD","LU0359201612.USD","BK0183","LU2097828631.EUR","LU1781817850.SGD","LU1146622755.USD","BK0239","LU2488822045.USD","LU2097828474.EUR","BK0188","LU1997244956.HKD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}